Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Phospholipase A2 | 1 | 2019 | 25 | 0.730 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2019 | 70 | 0.690 |
Why?
|
| Hypernatremia | 1 | 2016 | 87 | 0.550 |
Why?
|
| Diuretics | 1 | 2016 | 588 | 0.460 |
Why?
|
| Antithrombins | 1 | 2013 | 302 | 0.400 |
Why?
|
| Blood Coagulation | 1 | 2013 | 1110 | 0.320 |
Why?
|
| Drug Monitoring | 1 | 2013 | 939 | 0.310 |
Why?
|
| Heparin | 1 | 2013 | 1620 | 0.290 |
Why?
|
| Graft Survival | 4 | 2021 | 3750 | 0.230 |
Why?
|
| Hemorrhage | 1 | 2013 | 3279 | 0.210 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 63 | 0.200 |
Why?
|
| Thrombosis | 1 | 2013 | 2843 | 0.190 |
Why?
|
| Anticoagulants | 1 | 2013 | 4375 | 0.170 |
Why?
|
| Heart Transplantation | 2 | 2020 | 3073 | 0.150 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2020 | 335 | 0.150 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 133 | 0.140 |
Why?
|
| Water-Electrolyte Balance | 1 | 2016 | 349 | 0.130 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 1014 | 0.130 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 1396 | 0.120 |
Why?
|
| Amphotericin B | 1 | 2013 | 142 | 0.120 |
Why?
|
| Antibodies | 1 | 2021 | 2432 | 0.120 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2011 | 133 | 0.100 |
Why?
|
| Histamine H2 Antagonists | 1 | 2011 | 169 | 0.100 |
Why?
|
| Graft Rejection | 2 | 2020 | 4396 | 0.090 |
Why?
|
| Health Services Misuse | 1 | 2011 | 242 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 702 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 2548 | 0.090 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 4140 | 0.080 |
Why?
|
| Critical Illness | 1 | 2020 | 2529 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 1974 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3451 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 4492 | 0.080 |
Why?
|
| Brazil | 2 | 2021 | 1169 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2011 | 480 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 1153 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 3045 | 0.070 |
Why?
|
| Kidney | 2 | 2021 | 6881 | 0.070 |
Why?
|
| Europe | 2 | 2021 | 3343 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2011 | 2539 | 0.060 |
Why?
|
| Transplantation, Homologous | 2 | 2020 | 4824 | 0.050 |
Why?
|
| Immune Tolerance | 2 | 2020 | 2313 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2020 | 211 | 0.050 |
Why?
|
| Recurrence | 2 | 2021 | 8240 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 623 | 0.040 |
Why?
|
| Isoantigens | 1 | 2020 | 582 | 0.040 |
Why?
|
| Male | 7 | 2021 | 350324 | 0.040 |
Why?
|
| Isoantibodies | 1 | 2020 | 666 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2020 | 780 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2016 | 175 | 0.030 |
Why?
|
| Humans | 10 | 2021 | 715777 | 0.030 |
Why?
|
| Middle Aged | 5 | 2021 | 214639 | 0.030 |
Why?
|
| Point Mutation | 1 | 2020 | 1651 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2016 | 23729 | 0.030 |
Why?
|
| Qatar | 1 | 2011 | 34 | 0.030 |
Why?
|
| United States | 4 | 2021 | 67905 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 6641 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 2480 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2020 | 2151 | 0.030 |
Why?
|
| Mycoses | 1 | 2013 | 365 | 0.020 |
Why?
|
| Risk Factors | 3 | 2021 | 70866 | 0.020 |
Why?
|
| Biopsy | 1 | 2021 | 6736 | 0.020 |
Why?
|
| Fibrosis | 1 | 2016 | 1928 | 0.020 |
Why?
|
| Autophagy | 1 | 2016 | 1314 | 0.020 |
Why?
|
| Female | 5 | 2021 | 377204 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5132 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4194 | 0.020 |
Why?
|
| Myocardium | 1 | 2020 | 4909 | 0.020 |
Why?
|
| Animals | 4 | 2020 | 169420 | 0.020 |
Why?
|
| Drug Approval | 1 | 2013 | 899 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 1330 | 0.020 |
Why?
|
| Adult | 4 | 2021 | 212266 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 1778 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 18784 | 0.010 |
Why?
|
| Mice | 2 | 2020 | 80375 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5111 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 20731 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10284 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2021 | 72443 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 22665 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 7311 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 18199 | 0.010 |
Why?
|
| Apoptosis | 1 | 2016 | 9973 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 23464 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40875 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7960 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 58323 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 62004 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 162448 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 51315 | 0.000 |
Why?
|
| Adolescent | 1 | 2011 | 85155 | 0.000 |
Why?
|
Concepts
(90)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(25)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_